Italmatch Chemicals to buy Solvay unit

By Luisa Beltran — 1 month ago

Italmatch Chemicals Group, a portfolio company of Ardian, has agreed to buy Solvay’s desalination and phosphonates and phosphonic acid-based water additives business. Financial terms weren’t announced. The deal is expected to close by the end of January.

Continue

$35.9M invested in Korea Advanced Materials Fund

By Barry Whyte — 5 years ago

International chemicals group Solvay, Korea Venture Investment Corp (KVIC) and AJU IB Investment have invested EUR26 million ($35.9 million) in the Korea Advanced Materials Fund. The fund will invest in renewable energy, printed electronics, clean technologies and green chemistry. Solvay will invest EUR 13 million ($17.9 million) and KVIC and AJU IB Investment will each put in EUR 6.5 million ($8.9 million). The Fund will be managed by AJU IB Investment.

Continue

Nycomed May Up Solvay Unit Bid as Sale Decision Looms

By PEHub Administrator — 6 years ago

LONDON (Reuters) – Nycomed, the private equity-owned Swiss drugmaker, is looking at sweetening its bid for Solvay’s (SOLB.BR) drugs unit with the Belgian chemical and drug maker’s board set to meet to decide on the unit’s future. Sources familiar with the matter said Solvay’s board would meet on either Friday or Saturday to discuss the […]

Continue

Nycomed Bids on Solvay

By PEHub Administrator — 6 years ago

LONDON (Reuters) – Nycomed, the private equity-owned Swiss drugmaker, recently made a fully financed 4 to 4.5 billion euro ($5.88 to $6.62 billion) offer to buy Solvay SA’s (SOLB.BR) drug unit, people familiar with the matter said. As reported by Reuters in August, Nycomed would fund any buyout of the Belgian pharmaceutical business by high-yield […]

Continue

Nycomed Bids for Solvay’s Pharma Business

By PEHub Administrator — 7 years ago

LONDON (Reuters) – Private-equity owned Nycomed and a Japanese drugs company are in the early second round of an auction for all of Solvay’s pharmaceuticals business, a person familar with the matter said on Wednesday. Analysts reckon the Belgian chemicals and drug maker’s Solvay Pharmaceuticals unit could fetch 5 billion euros ($7 billion) or more, […]

Continue